✨ Free AI Report
2seventy bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview 2seventy bio, Inc.
Research Preview

2seventy bio, Inc.: Business Overview, Financials & Competitive Analysis

2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. In March 2026, Bristol Myers Squibb announced an agreement to acquir...

Analyst-debate audio for 2seventy bio, Inc.

AskCyborg analysts argue the bull and bear cases for 2seventy bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
2seventy bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Acquisition by BMS at $5/share signals partial value recovery after strategic repositioning, but underlying biotech execution...

Read the full analyst-debate transcript →
Industry CAR T cell immunotherapy
4 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 29, 2026
AI-Verified Research
30+ Page Report

Get the Latest 2seventy bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

2seventy bio, Inc. Overview

Pro stress-test →

2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. In March 2026, Bristol Myers Squibb announced an agreement to acquire 2seventy bio for approximately $286 million, with BMS commencing a tender offer to acquire all outstanding shares at $5.00 per share in an all-cash transaction.

Strategic Profile

Pro stress-test →

Following a strategic focus initiated in 2024 to unlock the value of Abecma, the company pursued exclusive focus on its BCMA-targeted CAR T therapy for multiple myeloma. The company's lead asset Abecma is a CAR T cell therapy targeting BCMA for treating multiple myeloma, developed and commercialized jointly by 2seventy bio and Bristol Myers Squibb in the U.S.

Competitive Landscape

Pro stress-test →

2seventy bio combines deep knowledge of cancer cell biology and genetics with understanding of immune response to cancer. The company competed in the immuno-oncology CAR T space alongside pure-play competitors and larger pharmaceutical players developing cellular therapies for hematologic malignancies.

Industry Context

2seventy bio, Inc. operates in CAR T cell immunotherapy.

Key facts

Founded: 2021 · Headquarters: Cambridge, US · Employees: 460 (as of 2021) · Revenue: Not disclosed · Market cap: $266M (as of January 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for 2seventy bio, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when 2seventy bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kite PharmaCAR T cell therapy for hematologic malignancies→Cellectis CAR TAllogeneic CAR T cell immunotherapy→Mustang Bio PipelineCAR T cell therapy developer→GT Biopharma TherapiesCAR T immunotherapy→

Compare 2seventy bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

2seventy bio, Inc. operates in CAR T cell immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse CAR T cell immunotherapy research →
NEW · MCP server

Ask your AI assistant about 2seventy bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 2seventy bio, Inc. and its top competitor on Cyborg Score”
“What did 2seventy bio, Inc. do this quarter?”
“Is 2seventy bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does 2seventy bio, Inc. do?+
2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. In March 2026, Bristol Myers Squibb announced an agreement to acquir...
What is 2seventy bio, Inc.'s Cyborg Score?+
2seventy bio, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 2seventy bio, Inc.'s main competitors?+
Named competitors include Kite Pharma, Cellectis CAR T, Mustang Bio Pipeline, GT Biopharma Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full 2seventy bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 2seventy bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 2seventy bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Phnom Penh Water Supply Authority9ESCO Technologies Inc.9Evolution Mining Limited9CoreWeave, Inc.9Nintendo Co., Ltd.9Waste Management, Inc.9CrowdStrike Holdings, Inc.9SK Hynix Inc.9Kweichow Moutai Co., Ltd.9Apple Inc.8Domino's Pizza, Inc.8Pro-Dex, Inc.8Palladyne AI Corp.8Mo-BRUK S.A.8Kuwait Reinsurance Company K.S.C.P.8Red River Bancshares, Inc.8PTC India Limited8IsoEnergy Ltd.